Showing results (11-20 of 60) with videos related to

Sort By:
Pageof 6
Cancers|August 23, 2020
Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in MyelofibrosisAndrew T Kuykendall, Nathan P Horvat, Garima Pandey, et al.
Cancers|December 17, 2024
Anemia in Myelofibrosis: A Focus on Proactive Management and the Role of MomelotinibHaifa Kathrin Al-Ali, Andrew T Kuykendall, Catherine E Ellis, et al.
American Journal of Hematology|November 4, 2018
Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patientsAndrew T Kuykendall, Chetasi Talati, Eric Padron, et al.
Expert Opinion on Pharmacotherapy|May 10, 2023
Moving beyond ruxolitinib failure in myelofibrosis: evolving strategies for second line therapyPrithviraj Bose, Andrew T Kuykendall, Carole Miller, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 16, 2026
Risk of Thromboembolic Events in Patients With Polycythemia Vera: A Real-World Observational StudyAndrew T Kuykendall, Arturo Molina, Nancy Reaven, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 4, 2022
Comparison of Different Treatment Strategies for Blast-Phase Myeloproliferative NeoplasmsFranco Castillo Tokumori, Najla Al Ali, Onyee Chan, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 12, 2020
Retrospective Analysis of the Clinical Use and Benefit of Lenalidomide and Thalidomide in MyelofibrosisFranco Castillo-Tokumori, Chetasi Talati, Najla Al Ali, et al.
Leukemia & Lymphoma|February 27, 2026
Ruxolitinib treatment for myelofibrosis with anemia: a retrospective assessment of real-world patient characteristics, treatment patterns, and survivalAndrew T Kuykendall, Francesca Palandri, Mirko Fillbrunn, et al.
Advanced Materials (Deerfield Beach, Fla.)|August 20, 2021
Single-Crystalline Diluted Magnetic Semiconductor GaN:Mn NanowiresH-J Choi, H-K Seong, J Chang, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 23, 2020
Fluorescence in Situ Hybridization (FISH) Utility for Risk Score Assessment in Patients With MDS With Normal Metaphase KaryotypeZaker I Schwabkey, Najla Al Ali, Onyee Chan, et al.
Pageof 6